<DOC>
	<DOCNO>NCT00229710</DOCNO>
	<brief_summary>This 140-week open-label , multi-center long-term extension study GALLANT 9 monitor safety tolerability oral tesaglitazar 0.5 mg insulin patient type 2 diabetes 140 week treatment . The total duration , include treatment follow-up , 143 week .</brief_summary>
	<brief_title>GALLEX 9 : Safety Tolerability Oral Tesaglitazar When Added Insulin Therapy Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Provision write informed consent Men woman &gt; = 18 year age Female patient : postmenopausal ; hysterectomized ; , childbearing potential , use reliable method birth control . Completed last two visit randomize treatment period GALLANT 9 Type 1 diabetes New York Heart Association heart failure Class III IV Treatment chronic insulin History hypersensitivity intolerance peroxisome proliferatoractivated receptor agonist ( like Actos Avandia ) , fenofibrate , metformin 3hydroxy3methylglutaryl coenzyme A reductase inhibitor ( statin ) History druginduced myopathy druginduced creatine kinase elevation , liver enzyme elevation , neutropenia ( low white blood cell ) Creatinine level twice normal range Creatine kinase 3 time upper limit normal Previous enrollment longterm extension study Any clinically significant abnormality identify physical examination , laboratory test electrocardiogram , judgment investigator , would compromise patient 's safety successful participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Diabetes Mellitus , Type II</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>